Beijing Med Pharm To Exclusively Market Novartis’ Enablex In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing Med-Pharm (BMP) entered into an exclusive licensing agreement Nov. 26 with Novartis subsidiary Shanghai Novartis Trading Limited, for its bladder treatment drug Enablex (darifenacin) in China
You may also be interested in...
Novartis’ Enablex Given Green Light for Clinical Trials By China’s SFDA
SHANGHAI - China's State FDA has officially accepted BMP Sunstone's clinical trial application for Novartis' Enablex (darifenacin), the company announced May 6.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).